<DOC> 
<DOCNO>1030211_business_story_1659708.utf8</DOCNO> 
<TEXT> 

The Telegraph - Calcutta : Business
 Tuesday, February 11, 2003 				 New bacteria drug from Ranbaxy 
 OUR CORRESPONDENT 																								New Delhi, Feb. 10: Ranbaxy Laboratories (RLL) today launched a new generation anti-infective in the cephalosporin category. The product is being introduced for the first time in India. 																								Launched under Ranbaxys own brand name of Refzil O, the drug is a high-end advanced cephalosporin  the generic name being Cefprozil, which is a sub-category of cephalosporin. 																								Refzil O, a high generation oral cephalosporin, is useful in combating different types of bacteria in surgical cases and respiratory tract infections, both among adults and children. 																								The cephalosporin market in India is estimated at around Rs 1,000 crore for the year 2002. It accounts for one-third of the anti-infectives market and is growing at the rate of 9 per cent. This is more than double the growth rate of the anti-infectives market. Ranbaxy already has two drugs of this category in its kitty  Sporidex and Keflor. 																								A Ranbaxy spokesperson said the brand would be a superior choice for the treatment of staphyloccal infections and will be an ideal follow-up therapy for patients after usage of injectable Refzil. 																								The global market size of this molecule is around $ 400 million and is among the top five selling cephalosporins out of more than 25 such molecules in this segment. 
</TEXT> 
</DOC>